Assessing the in vivo impact of novel β-lactamase inhibitors on the efficacy of their partner β-lactams against serine carbapenemase-producing Pseudomonas aeruginosa using human-simulated exposures.
Victor H RuizChristian M GillDavid P NicolauPublished in: The Journal of antimicrobial chemotherapy (2024)
Ceftazidime/avibactam and imipenem/relebactam were active against 100% and 89% of KPC- or GES-harbouring isolates tested in vivo. The activity of meropenem/vaborbactam was variable, suggesting this may be an inferior treatment option in this setting. Further studies to evaluate clinical outcomes in GES- and KPC-producing P. aeruginosa are warranted given their increasing prevalence worldwide.
Keyphrases
- klebsiella pneumoniae
- gram negative
- multidrug resistant
- pseudomonas aeruginosa
- escherichia coli
- acinetobacter baumannii
- endothelial cells
- drug resistant
- cystic fibrosis
- risk factors
- air pollution
- induced pluripotent stem cells
- pluripotent stem cells
- biofilm formation
- case control
- men who have sex with men
- candida albicans